Research and Clinical Trials on Sertraline (Zoloft, Lustral)

By Dr Greg Mulhauser
avatar image

This list of current clinical research trials on Sertraline (Zoloft, Lustral) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Sertraline (Zoloft, Lustral) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Sertraline (Zoloft, Lustral).

 

Get These Clinical Trials as a Newsfeed

Sertraline:     Get the Sertraline clinical trials feed.    Add the Sertraline clinical trials feed to your My Yahoo! page.    Add the Sertraline clinical trials feed to your MyMSN page.

Current Research Literature on Sertraline (Zoloft, Lustral)

Here are abstracts for some of the latest research articles to have appeared on Sertraline (Zoloft, Lustral):

Comparison of drug concentrations taken from clamped and unclamped femoral vessels.

J Anal Toxicol. 2008 Oct; 32(8): 621-5
Hargrove VM, McCutcheon JR
Postmortem drug concentrations may vary depending on sampling site, volume of blood collected, and method of sampling, making it important to analyze specimens from different sites in the body to detect postmortem redistribution and avoid erroneous conclusions on cause and manner of death. Using a blind stick method to draw large amounts of blood from the femoral vessel may increase the likelihood of contamination with blood from more central sites. It has been suggested that clamping the femoral vessel before drawing the sample may eliminate possible contribution from central sites. Eight drugs from four different drug classes were evaluated to determine the difference between drug concentrations in clamped and blind stick femoral blood. Drug concentrations of three selective serotonin reuptake inhibitors, or SSRIs (sertraline, paroxetine, citalopram), two benzodiazepines (diazepam and alprazolam), two antihistamines (diphenhydramine and promethazine), and one opiate (hydrocodone) were evaluated in clamped femoral blood, blind stick femoral blood, and heart blood and compared using concentration ratios and linear regression analysis. Clamped femoral blood concentrations and blind stick femoral blood concentrations were found to have good predictability across all drug classes with ratios around 1.0, indicating good correlation between blind stick femoral and clamped femoral samples. Therefore, it can be concluded that a blind stick femoral blood sample does not have significant redistribution from central sites and is of equivalent quality to a clamped femoral sample.

Sertraline in the treatment of depressive disorders in patients with Parkinson's disease.

Neurol Sci. 2008 Nov 11;
Marino S, Sessa E, Di Lorenzo G, Digangi G, Alagna A, Bramanti P, Di Bella P
We studied 54 idiopathic Parkinson's disease (PD) patients with depressive disorders (DD) to compare the efficacy and the effect of treatment with sertraline in the usual formulation and in the liquid oral concentrate (LOC) formulation. After 6 months of sertraline treatment, the Hamilton Depression Rating Scale and the Montgomery and Asberg Depression Rating Scale showed a decrement (p

[Physico-chemical profiling of centrally acting molecules for prediction of pharmacokinetic properties]

Acta Pharm Hung. 2008; 78(3): 110-20
Deák K
Physico-chemical profiling is a fundamental tool at the early stage of drug discovery in screening drug-like candidates. Complex physico-chemical profiling, including molecular properties such as solubility, ionization, lipophilicity and permeability, has been found to be of predictive power in ADME (absorption, distribution, metabolism, elimination). In the present thesis work, the physico-chemical properties of centrally acting compounds were investigated. We determined the protonation constants (K), the partition coeffitient in octanol/water (Poct) and cyclohexane/water (Pch) systems of antidepressive sertraline and 15 antipsychotic piperidine and piperazine derivatives and calculated the delta logP (logPoct-logPch) values of the molecules. Due to the poor water solubility of the compounds potentiometry using the "co-solvent" technique was applied for the determination of the protonation constants. The logP values were measured by the dual-phase potentiometric titration in octanol/water system and the traditional shake-flask method was used in cyclohexane/water system. Highly precise physico-chemical data were obtained by these validated methods. The relationship between the structure of the molecules and the physico-chemical data was investigated. The pharmacokinetic properties of the compounds were predicted by the physico-chemical parameters. Linear relationship has been found between the brain penetration characterized by the logBB values and the delta logP values. The validity of the equation was controlled by the delta logP and the logBB values of sertraline.

Analytical methodologies for the determination of sertraline.

J Pharm Biomed Anal. 2008 Sep 30;
Bosch ME, Sánchez AJ, Rojas FS, Ojeda CB
Sertraline is a widely used antidepressant belonging to the selective serotonin reuptake inhibitor class; its efficacy has been demonstrated not only in the treatment of major depression, obsessive compulsive and panic disorders, but also for eating, premenstrual dysphoric and post-traumatic stress disorders. Several methods have been published for the determination of sertraline in pharmaceuticals, biological materials and environmental samples. The purpose of the current review is to provide a systematic survey of the latest analytical techniques for the determination of sertraline covering the period from 1987 until 2008.

Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety.

N Engl J Med. 2008 Oct 31;
Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC
BACKGROUND: Anxiety disorders are common psychiatric conditions affecting children and adolescents. Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown efficacy in treating these disorders, little is known about their relative or combined efficacy. METHODS: In this randomized, controlled trial, we assigned 488 children between the ages of 7 and 17 years who had a primary diagnosis of separation anxiety disorder, generalized anxiety disorder, or social phobia to receive 14 sessions of cognitive behavioral therapy, sertraline (at a dose of up to 200 mg per day), a combination of sertraline and cognitive behavioral therapy, or a placebo drug for 12 weeks in a 2:2:2:1 ratio. We administered categorical and dimensional ratings of anxiety severity and impairment at baseline and at weeks 4, 8, and 12. RESULTS: The percentages of children who were rated as very much or much improved on the Clinician Global Impression-Improvement scale were 80.7% for combination therapy (P

 

This page was last reviewed by Dr Greg Mulhauser, Friday, 4 July 2008.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/sertraline-research.html